Abstract:Dear Editor, Due to a different mutation site in the Duchenne muscular dystrophy (DMD) gene, patients with Becker muscular dystrophy (BMD) show a milder and slower clinical progression as compared with patients with DMD. Cardiac involvement is a frequent feature of both dystrophies, which can develop before or after skeletal muscle damage. Asymptomatic cardiomyopathy is seen in most cases, and left- or bi-ventricular dilation occurs in up to one-third of patients with BMD [1]. In contrast, left ventricular (LV) hypertrophy has rarely been reported. A 32-year-old male patient was admitted with the chief complaint of exertional dyspnea and fatigue accompanied by mild muscular pain and weakness in the lower extremities for 2 years. Mildly enlarged cardiac dullness, pseudohypertrophy of the calf muscles, Gowers sign, and mild muscular weakness and tenderness in the lower extremities were present on physical examination. Laboratory tests showed very high levels of myogenic and myocardiogenic enzymes, including a cytokinase (CK) of 4730 IU/L (normal range: 19–226 IU/L), lactate dehydrogenase of 838 IU/L (110–220 IU/L), myoglobin of 966 ng/mL (28–72 ng/mL), CK-MB > 300 ng/L (< 4.94 ng/L), and Troponin-T of 80 ng/L (< 14 ng/L). The level of serum N-terminal-pro-brain natriuretic peptide was 512 pg/mL (0–88 pg/ml). The echocardiogram (ECG) demonstrated LV hypertrophy with increased R-wave amplitude and inverted T-wave in the left-sided ECG leads (V5, V6, I, and AVL). Two-dimensional echocardiography revealed severe LV hypertrophy, normal LV end-diastolic dimensions, and a preserved LV-ejection fraction. Neither an outflow tract obstruction nor mitral leaflet systolic anterior motion was detected (Figure 1A). Moreover, delayed enhancement of the myocardium was detected by cardiac magnetic resonance (CMR) (Figure 1B). The electromyogram displayed myogenic damage, but normal nerve conduction. Consequently, a skeletal muscle biopsy with specific immunohistochemistry showed positive expression of dysferlin and α, β, γ, and δ-sarcoglycan, but the intensity indicated decreased N-terminal, C-terminal, and rod-domain dystrophin, which helped to confirm BMD (Figure 1C as compared to normal skeletal muscle cells from another patient shown in Figure 1D; informed consent was obtained from the patients to publish their data). Unfortunately, this patient refused genetic testing. (A) Hypertrophic IVS and LVPW at the parasternal long-axis view by echocardiography. (B) Hypertrophic anterior septum with delayed gadolinium enhancement (arrow) at the long-axis two-chamber view by cardiac magnetic resonance. (C) Longitudinal section of skeletal muscle cells from this patient, showing negative C-terminal dystrophin at most of the muscle cell membranes (black arrow) and C-terminal dystrophin with abnormal phenotype at a few sites (white arrow) by immunohistochemical staining (200×). (D) As a reference, cross-section of normal skeletal muscle cells from the amputated limb of a patient with traffic injury, showing uniform and intense C-terminal dystrophin at every muscle cell membrane (white arrow) by immunohistochemical staining (200×). IVS = interventricular septum; LVPW = left-ventricular posterior wall. X-linked DMD and BMD are allelic disorders caused by mutations in the DMD gene. The gene mainly encodes dystrophin, which is primarily localized at the surface membrane of striated muscle fibers and is expressed in similar isoforms in skeletal, cardiac, and smooth muscle. In DMD, dystrophin is nearly absent. Severe skeletal muscle involvement occurs at a very young age and rapidly progresses to akinesia within a few years. In contrast, dystrophin remains present at some concentration, but shows an abnormal phenotype in BMD [1]. Similar to this case, BMD patients usually present later in life, with mild skeletal muscular symptoms of slower progression; however, these patients usually have obvious symptoms of cardiac involvement. Because a dystrophin deficiency makes muscular cells vulnerable to the damage caused by mechanical stress, necrotic myocytes are replaced by connective tissue fibers and fat [2]. However, there is great variability in the degree of cardiac involvement in BMD. As previously reported, different types of ECG abnormalities are frequently observed in BMD. Not surprisingly, morphological changes in the myocardium usually manifest as LV or biventricular chamber dilation [3]. Delayed gadolinium enhancement in the dilated LV via CMR was also reported [4]. In contrast, LV hypertrophy (as in this case) is extremely rare in both BMD and DMD. There was one case reported of a 17-year-old boy with BMD who presented with a rapid progression from hypertrophic cardiomyopathy to heart failure within 2 years [5]. Therefore, myopathy should be considered when LV hypertrophy is accompanied by myalgia, difficulty in moving, and increased myogenic enzymes. Muscle biopsy and genetic testing may help confirm the diagnosis. This study was supported by a research grant (2012SZ0029) from the Department of Science and Technology, Sichuan, China.

Electrophysiologic and cardiovascular manifestations of Duchenne and Becker muscular dystrophies

Duchenne muscular dystrophy: an overview to the cardiologist

Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges

Systemic under treatment of heart disease in patients with Duchenne muscular dystrophy

Diverse Cardiac Phenotype of Becker Muscular Dystrophy: Under-Recognized Subclinical Cardiomyopathy Due to Partial Dystrophin Deficiency in a Contemporary Era

Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response

Cardiac medication management in Duchenne muscular dystrophy

The multifaceted view of heart problem in Duchenne muscular dystrophy

Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: A systematic review

356P A retrospective review of adult Duchenne muscular dystrophy patients in a UK centre of excellence and report the results of adherence to the standards of care guidelines for cardiac management

Abstract 310: Mechanistic Insights into Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Predictors of cardiac disease in duchenne muscular dystrophy: a systematic review and evidence grading

The association between cardiac involvement and long-term clinical outcomes in patients with Duchenne muscular dystrophy

Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study

Cardiomyopathies Caused by Pathogenic Variants in the DMD Gene

Cardiac atrial pathology in Duchenne muscular dystrophy

Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies

Cardiac Involvement in Emery-Dreifuss Muscular Dystrophy and Related Management Strategies.

Duchenne Muscular Dystrophy and Dilated Cardiomyopathy with Deletion of Exon 45 and 49

Prevalence and clinical outcomes of dystrophin‐associated dilated cardiomyopathy without severe skeletal myopathy

Left Ventricular Hypertrophy: A Rare Cardiac Involvement of Becker Muscular Dystrophy